Latest News
US Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Programme with Three New Phase 3 Trials
15 February 2019 - - US-based biopharmaceutical company Merck (NYSE: MRK) has presented interim data from the Phase 1b/2 KEYNOTE-365 umbrella trial investigating Keytruda, Merck's anti-PD-1 therapy, in combination with various agents for the tre...
Boehringer Ingelheim and Lilly's CAROLINA Cardiovascular Outcome Trial for Trajenta Meets Primary Endpoint of Non-Inferiority Compared to Glimepiride
15 February 2019 - - German pharmaceutical company Boehringer Ingelheim and US-based Eli Lilly and Company's (NYSE: LLY) CAROLINA (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its prim...
Affinivax Initiates Phase 1/2 Clinical Study of ASP3772, Its Novel Pneumococcal MAPS Vaccine, in Collaboration with Astellas
15 February 2019 - - The first subject has been dosed with ASP3772, US-based Affinivax, Inc.'s novel MAPS vaccine targeting Streptococcus pneumoniae (pneumococcus), the company said.

The clinical study protocol "A Pha...
Leiters partners with Mobius Therapeutics for marketing of Mitosol
15 February 2019 - Medication company Leiters disclosed on Thursday the launch of a national sales and marketing agreement for the ophthalmic product Mitosol from Mobius Therapeutics.Mobius Therapeutics' first product, Mitosol, is the only US FD...
Spring Pharmaceutical Group posts higher net income of USD12.91m for the nine months ended 31 December 2018
15 February 2019 - Health care supplement products Spring Pharmaceutical Group Inc (OTCQB:CYIG) stated on Thursday its net income of USD12.91m (USD0.43 per basic and diluted share) for the nine months ended 31 December 2018.This marks an improvement ...